Search results for "Pancreatic carcinoma"

showing 10 items of 15 documents

Preclinical evaluation of the anti-CLDN18.2 antibody, IMAB362, in pancreatic carcinoma

2017

0301 basic medicineOncologymedicine.medical_specialtybiologybusiness.industryHematologymedicine.disease03 medical and health sciences030104 developmental biology0302 clinical medicineOncology030220 oncology & carcinogenesisPancreatic cancerInternal medicinebiology.proteinmedicineCA19-9Pancreatic carcinomaAntibodybusinessIMAB362Annals of Oncology
researchProduct

Irinotecan Plus Bolus/Infusional 5-Fluorouracil and Leucovorin in Patients With Pretreated Advanced Pancreatic Carcinoma

2010

Patients with advanced pancreatic cancer failing gemcitabine-based first-line chemotherapy are still in relatively good clinical conditions and may still require second-line chemotherapy, which is frequently administered in daily clinical practice given to without solid scientific support.A retrospective survey was carried out including 40 patients with stage III or IV gemcitabine-refractory pancreatic carcinoma. Patients received standard FOLFIRI regimen biweekly until progression or unacceptable toxicity. Response evaluation criteria in solid tumors and National Cancer Institute common toxicity criteria were employed respectively for response and toxicity assessment.Six partial responses …

AdultMaleOncologyCancer Researchmedicine.medical_specialtyDrug-Related Side Effects and Adverse Reactionsmedicine.medical_treatmentLeucovorinIrinotecanBolus (medicine)Pancreatic cancerInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineFOLFIRI RegimenHumansPancreatic carcinomaAgedRetrospective StudiesChemotherapybusiness.industryMiddle Agedmedicine.diseaseSurvival AnalysisGemcitabinePancreatic NeoplasmsIrinotecanOncologyFluorouracilCamptothecinFemaleFluorouracilbusinessmedicine.drugAmerican Journal of Clinical Oncology
researchProduct

Second-line chemotherapy in advanced pancreatic carcinoma: a multicenter survey of the Gruppo Oncologico Italia Meridionale on the activity and safet…

2007

Background: In daily clinical practice second-line chemotherapy (SLCT) is frequently given to patients with advanced pancreatic cancer failing gemcitabine-based first-line chemotherapy without solid scientific support. Patients and methods: A retrospective survey was carried out including 42 patients. Patients received standard FOLFOX4 regimen biweekly until progression or unacceptable toxicity. Results: Six partial responses (14%) and 16 stabilizations (38%) were recorded for a tumor growth control rate of 57%. The median time to progression (TtP) was 4 months (range 1–7 months), and median overall survival (OS) was 6.7 months (range 2–9 months). A stabilization of performance status (PS) …

AdultMalemedicine.medical_specialtyPancreatic diseaseOrganoplatinum Compoundsmedicine.medical_treatmentLeucovorinAdenocarcinomaInternal medicinePancreatic cancerAntineoplastic Combined Chemotherapy ProtocolsMedicineHumansAgedRetrospective StudiesChemotherapyPerformance statusbusiness.industryCancerHematologyMiddle Agedmedicine.diseaseChemotherapy regimenGemcitabineDrug Resistance MultipleSurgeryPancreatic NeoplasmsFOLFOX4 regimen pancreatic carcinoma second-line chemotherapyRegimenOncologyChemotherapy AdjuvantDrug Resistance NeoplasmFemaleFluorouracilbusinessmedicine.drug
researchProduct

PANCREATIC CARCINOMA VERSUS CHRONIC FOCAL PANCREATITIS: CONTRAST-ENHANCED POWER DOPPLER ULTRASONOGRAPHY FINDINGS

2005

Background: We assessed the potential usefulness of contrast-enhanced power Doppler ultrasonography (US) for differentiating pancreatic carcinoma from chronic focal pancreatitis. Methods: Twenty-six consecutive patients with ductal carcinoma (n=16) and chronic focal pancreatitis (n=10) underwent power Doppler US examinations before and after intravenous injection of an air-based contrast agent (Levovist, Schering, Berlin, Germany). Final diagnosis was obtained by surgery in all patients. The following parameters before and after intravenous administration of contrast agent were evaluated for each lesion: number, morphology and course of the vessels within the lesion and time to maximum dete…

AdultMalemedicine.medical_specialtyPancreatic diseasechronic focal pancreatitiUrologyContrast MediaAdenocarcinomaDiagnosis DifferentialLesionPolysaccharidesInternal medicinemedicineCarcinomaHumansRadiology Nuclear Medicine and imagingAgedRetrospective Studiespower Doppler ultrasonographyRadiological and Ultrasound Technologypancreatic carcinomabusiness.industryultrasoundUltrasoundGastroenterologyUltrasonography DopplerGeneral MedicineMiddle AgedDuctal carcinomaHepatologymedicine.diseasePancreatic NeoplasmsPancreatitisChronic DiseaseInjections IntravenousPancreatitisFemaleRadiologymedicine.symptombusinessBlood Flow Velocitycontrast-enhanced ultrasoundContrast-enhanced ultrasound
researchProduct

Early prediction of pancreatic cancer from new-onset diabetes: an Associazione Italiana Oncologia Medica (AIOM)/Associazione Medici Diabetologi (AMD)…

2021

Pancreatic cancer (PC) is a common cause of cancer-related death, due to difficulties in detecting early-stage disease, to its aggressive behaviour, and to poor response to systemic therapy. Therefore, developing strategies for early diagnosis of resectable PC is critical for improving survival. Diabetes mellitus is another major public health problem worldwide. Furthermore, diabetes can represent both a risk factor and a consequence of PC: nowadays, the relationship between these two diseases is considered a high priority for research. New-onset diabetes can be an early manifestation of PC, especially in a thin adult without a family history of diabetes. However, even if targeted screening…

Cancer Researchmedicine.medical_specialtyConsensusReviewDiseaseMedical OncologySystemic therapyNOconsensus; diabetes; early diagnosis; hyperglycaemia; pancreatic carcinoma; Consensus; Humans; Medical Oncology; Diabetes Mellitus; Pancreatic Neoplasms; PhysiciansDiabetes mellitusPancreatic cancerPhysiciansmedicineDiabetes MellitusHumansFamily historyRisk factorLS4_3Intensive care medicinediabetes pancreatic carcinoma early diagnosis consensus hyperglycaemiadiabetespancreatic carcinomabusiness.industryPublic healthmedicine.diseasePancreatic NeoplasmsOncologyPosition paperbusinesshyperglycaemiaearly diagnosis
researchProduct

Wertigkeit der pr�operativen Diagnostik zur Beurteilung der Tumorausdehnung bei ductalen Pankreascarcinomen

1990

Fur die Therapieplanung beim Pankreascarcinom kann die Wertigkeit der praope-rativen Beurteilung der Tumorausdehnng von Bedeutung sein. Bei 449 Patienten wurde retrospektiv und bei 35 Patienten prospektiv die Wertigkeit der praoperativen Diagnostik in der Beurteilung dieser Fragestellung uberpruft. Dabei zeigte sich, das nur die Kombination von Angiographie und Computertomographie eine Aussage zur Gefasinfiltration mit einer Treffsicherheit von 90% ermoglicht. Lebermetastasen wurden retrospektiv in 80% und prospektiv in 66,7% (Sonographie) bzw. 58,3% (Computertomographie) bei einer Spezifitat von 86,9% bzw. 91,3% erkannt. Diese Ergebnisse bestatigen das bisherige Therapiekonzept, das nur be…

Gynecologymedicine.medical_specialtybusiness.industryMedicineSurgeryPancreatic carcinomabusinessLangenbecks Archiv fur Chirurgie
researchProduct

Clinical efficacy of nab-paclitaxel in patients with metastatic pancreatic cancer

2018

Rossella De Luca,1 Livio Blasi,2 Massimiliano Alù,2 Valerio Gristina,1 Giuseppe Cicero1 1Department of Surgical, Oncological and Oral Sciences, Section of Medical Oncology, University of Palermo, Palermo, Italy; 2Medical Oncology Unit, ARNAS Hospital Civico, Di Cristina, Benfratelli, Palermo, Italy Purpose: Pancreatic carcinoma is the neoplasia with the major mortality, and main standard treatments in this cancer increase survival but do not lead to complete recovery of the patient. The aim of this study was to evaluate the efficacy of Abraxane® (nab-paclitaxel) in Italian patients with metastatic pancreatic cancer (MPC).Patients and methods: We conducted a retrospective …

Male0301 basic medicineOncologyTime Factorsmedicine.medical_treatmentPharmaceutical ScienceKaplan-Meier EstimatechemotherapyMetastasis0302 clinical medicineRisk FactorsDrug DiscoveryClinical endpointOriginal ResearchMiddle AgedTreatment OutcomeItalyTolerabilityCA 19-9030220 oncology & carcinogenesisFemaleCA19-9medicine.drugmedicine.medical_specialtyCA-19-9 AntigenPaclitaxeloverall survivalPainAntineoplastic AgentsAdenocarcinomaDisease-Free SurvivalAbraxane03 medical and health sciencesAlbuminsInternal medicinemedicineHumansmetastasisAbraxane chemotherapy pancreatic carcinoma metastasis CA 19-9 pain overall survivalSurvival rateAgedRetrospective StudiesPharmacologyChemotherapyDrug Design Development and Therapypancreatic carcinomabusiness.industryCancermedicine.diseaseGemcitabinePancreatic Neoplasms030104 developmental biologyLinear ModelsAlbumin-Bound PaclitaxelbusinessDrug Design, Development and Therapy
researchProduct

Imaging features of pancreatic metastases: A comparison with pancreatic ductal adenocarcinoma

2018

Purpose: To compare imaging features of pancreatic metastases (PM) with those of pancreatic ductal adenocarcinomas (PDAC). Methods: CT and MR scans of 24 patients with 54 PM and 30 patients with PDAC were reviewed to evaluate the imaging features, which were compared by using a Chi square test. Results: We found a statistically significant difference between PM and PDAC based on location (P < 0.001), margins (P < 0.001), arterial enhancement (P = 0.004), rim enhancement (P < 0.001), pancreatic duct dilatation (P = 0.01), common bile duct dilatation (P = 0.003), vascular involvement (P = 0.02), parenchymal atrophy (P < 0.001), peripancreatic fluid (P = 0.03). Conclusion: Imaging features mig…

Malemedicine.medical_specialtyRadiology Nuclear Medicine and ImagingPancreatic ductal adenocarcinomaLung Neoplasmsendocrine system diseasesMetastaseComputed tomographyAdenocarcinoma030218 nuclear medicine & medical imaging03 medical and health sciences0302 clinical medicinemedicineHumansAbdominal radiology; Adenocarcinoma; Computed tomography; Magnetic resonance; Metastases; Pancreas; Radiology Nuclear Medicine and ImagingPancreaPancreatic carcinomaCarcinoma Renal CellComputed tomographyAgedRetrospective StudiesAged 80 and overmedicine.diagnostic_testbusiness.industrySignificant differenceMagnetic resonance imagingNeoplasms Second PrimaryMiddle Agedmedicine.diseaseMagnetic Resonance ImagingAbdominal radiologydigestive system diseasesKidney NeoplasmsPancreatic Neoplasmsmedicine.anatomical_structureMagnetic resonance030220 oncology & carcinogenesisAdenocarcinomaFemaleRadiologybusinessPancreasTomography X-Ray ComputedCarcinoma Pancreatic Ductal
researchProduct

Non‐bacterial thrombotic endocarditis in a patient with pancreatic carcinoma

2021

Nonbacterial thrombotic endocarditis (NBTE) is a rare condition that most often accompanies a malignant disease and involves a hypercoagulable state. We report the incidental finding of a rare case of an NBTE affecting the tricuspid valve in a patient with metastatic pancreatic carcinoma complicated by severe venous and arterial thromboembolisms.

Metastatic Pancreatic Carcinomamedicine.medical_specialtyTricuspid valvebusiness.industrymedicine.diseaseNonbacterial thrombotic endocarditisGastroenterologyMalignant diseasemedicine.anatomical_structureInternal medicineRare caseMedicineEndocarditisRadiology Nuclear Medicine and imagingPancreatic carcinomaCardiology and Cardiovascular MedicinebusinessEchocardiography
researchProduct

Design of Bimodal Ligands of Neurotensin Receptor 1 for Positron Emission Tomography Imaging and Fluorescence-Guided Surgery of Pancreatic Cancer

2020

International audience; Neurotensin receptor 1 (NTSR1) is overexpressed in most human pancreatic ductal adenocarcinomas. It makes it an attractive target for the development of pancreatic cancer imaging agents. In this study, we sought to develop a bimodal PET-fluorescent imaging agent capable of specifically targeting these receptors. Starting from the structure of a known NTSR1 agonist, a series of tracers was synthesized, radiometalated with gallium-68 and evaluated in vitro and in vivo, in mice bearing an AsPC-1 xenograft. PET imaging allowed us to identify the compound [ 68 Ga]Ga-NODAGA-Lys(Cy5**)-AEEAc-[Me-Arg 8 , Tle 12 ]-NT(7-13) as the one with the most promising biodistribution pr…

Neurotensin receptor 1positron emission tomographydual-modality[SDV]Life Sciences [q-bio]Gallium RadioisotopesAcetatesLigands01 natural sciencesHeterocyclic Compounds 1-RingMice03 medical and health sciencesgallium-68Cell Line TumorPancreatic cancerDrug DiscoverymedicineAnimalsHumansReceptors Neurotensin[CHIM]Chemical SciencesPancreatic carcinomaPancreasNeurotensinFluorescent Dyes030304 developmental biology0303 health sciencesmedicine.diagnostic_testChemistryOptical Imagingmedicine.diseaseFluorescence0104 chemical sciencesPancreatic Neoplasms010404 medicinal & biomolecular chemistrySurgery Computer-AssistedPositron emission tomographyPositron-Emission TomographyCancer researchMolecular MedicineFemalefluorescence-guided surgery
researchProduct